What NRx Pharmaceuticals (NRXP) Said on Its Q3 Earnings Call

NRx Pharmaceuticals (NASDAQ:NRXP) reported higher third-quarter patient revenue and a narrower net loss, while outlining plans to commercialize its first approved drug and advance experimental treatments for depression and other conditions.

The company’s preservative-free ketamine product received Food and Drug Administration approval on October 29, after the quarter ended. Founder, Chairman and Chief Scientist Jonathan Javitt said NRx had received its first order the day before the earnings call, though he declined to disclose its size.

Javitt said the company aims to demonstrate a path to profitability in 2027. NRx is operating through four divisions: its pharmaceutical business, HOPE Therapeutics clinics, NRx Defense Systems and GeNeuro.

Quarterly Results and Cash Position

Net patient revenue rose to $1.2 million for the quarter ended September 30, 2026, from $0.2 million a year earlier, Chief Financial Officer Michael Abrams said. The net loss narrowed to $2.2 million, or $0.05 per share, from $5.9 million, or $0.27 per share, in the comparable quarter of 2025.

The operating loss widened to $8.1 million from $4 million in the prior quarter. For the first nine months of 2026, the operating loss was $19.4 million, compared with $11.6 million a year earlier. Abrams attributed the increase to higher costs at HOPE clinics as revenue grew, increased research and development spending, and commercial launch expenses.

NRx ended September with $19.8 million in cash and cash equivalents, up from $7.8 million at the end of 2025. Abrams said the increase primarily reflected a common-stock offering that generated more than $22 million in gross proceeds. Management believes its cash, expected revenue and potential use of its at-the-market offering facility will support operations for the foreseeable future.

Ketamine Launch and Depression Filing

Javitt said the newly approved preservative-free ketamine is aimed primarily at hospitals and hospital outpatient departments, where ketamine is used for anesthesia and pain control. The company has a 17-person sales force, he said, and the product is currently labeled “ketamine preservative-free.”

NRx developed the product with partner Nephron Pharmaceuticals using a blow-fill-seal vial with a Luer lock connection. Javitt said the packaging allows staff to draw medication without first piercing a traditional glass vial with a needle. He estimated the company’s cost of goods at approximately $0.75 per unit, compared with roughly $3.25 for glass packaging.

Separately, NRx hopes to begin a rolling new drug application for NRX-100, its ketamine program for depression and suicidality, by the end of 2026. The company plans to pursue both regular and accelerated approval, Javitt said.

NRx has signed a collaboration agreement with Yale University to join as a sponsor of a five-year study comparing intravenous ketamine with intranasal esketamine. Javitt said the company expects the study to provide confirmatory evidence if NRX-100 receives accelerated approval. He said NRx believes the product could be approved in 2027; approval remains subject to FDA review.

Pipeline and Defense Contract

NRx also introduced NRX-200, an experimental subcutaneous ketamine formulation. Javitt said pharmacokinetic testing is expected to begin in early 2027, with a first-in-human trial targeted for September 2027 at HOPE Therapeutics.

For NRX-101, an oral combination of D-cycloserine and lurasidone, NRx Defense Systems is leading the DARPA-funded SPARC-TMS trial. The study is designed to evaluate the drug alongside rapid robotic transcranial magnetic stimulation, or TMS. Javitt said the initial prime contract is worth $11.2 million and that the first two invoices had been approved for payment in the fourth quarter.

Including a planned military hospital arm, more than 400 patients are expected to be enrolled and treated in 2027, with SPARC-TMS results scheduled for early 2028, Javitt said. A positive result could support an application for approval, he said.

Clinics and GeNeuro

HOPE Therapeutics operated six Florida locations as of September 30, Javitt said. He added that the division has partnered with Zeta Surgical to use robotic, neuro-navigated TMS and has treated its first patients with the technology.

At GeNeuro, NRx is pursuing early-stage programs for amyotrophic lateral sclerosis, or ALS, and schizophrenia. Javitt said the ALS antibody candidate GNK-301 is intended for a biologically defined subgroup and described preclinical work involving a protein associated with the disease. GeNeuro also plans to test the antibody temelimab for schizophrenia.

NRx plans to hold a GeNeuro science day in the first week of December. Javitt said the company expects government and private investors to help fund the division, with an aim of limiting dilution to NRx shareholders.

About NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a focus on depression and conditions involving suicidal ideation. Its programs are investigational and have not been established as approved treatments. The company’s candidates include NRX-100, a preservative-free formulation of ketamine, and NRX-101, an oral combination of D-cycloserine and lurasidone. NRx has studied these therapies for severe depression and bipolar depression, including in patients with suicidal ideation.